AUTHORS
Sara M. Tinsley-Vance, PhD, APRN, AOCN, Ram Thapa, PhD2, Cecile A Lengacher, RN, PhD, FAAN, FAPOS3, Steven K. Sutton, PhD4, Martine Extermann, MD, PhD5, Areej R El-Jawahri, MD6, Rami Komrokji, MD7, Onyee Chan, MD8, David Sallman, MD9, Alison Walker, MD10, Andrew T Kuykendall, MD11, Eric Padron, MD12, Heather Buffington, DNP13, Kristan Kersey, PA-C14, Kathryn Herricks, APRN15, Yi Luo, PhD16, Seongseok Yun, MD, PhD17, Daniel Lastorino, BA18, Jeffrey Lancet, MD19
AFFILIATIONS
1 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
2 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
3 University of South Florida, Tampa, Florida, United States
4 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
5 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
6 Massachusetts General Hospital, Boston, Massachusetts, United States
7 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
8 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
9 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
10 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
11 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
12 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
13 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
14 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
15 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
16 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
17 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
18 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
19 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
ABSTRACT
Background: Shared decision-making in older adults with AML requires consideration of both survival and quality-of-life (QOL) outcomes. Many patients prioritize maintaining independence, function, and overall well-being as much as, or more than, extending survival. Nevertheless, QOL data that can inform treatment selection remain scarce. Understanding how treatment options differ with respect to patient-reported outcomes (PRO) is critical, as patients frequently seek information on the expected QOL tradeoffs associated with each therapeutic approach.
A time-to-deterioration (TTD) analysis is one method used in longitudinal oncology PRO studies to evaluate how long it takes for patients’ symptoms, functioning or QOL to worsen by a clinically meaningful point. This type of analysis is suited for informing discussions with patients who seek information on QOL, and symptoms associated with treatment options.
The objective of this study was to compare time to clinically meaningful deterioration in QOL and symptom scores among older adults with AML receiving intensive versus non-intensive treatment.
Methods: This exploratory, hypothesis-generating analysis used prospectively collected data from the NIH-funded study, Development of a Quality-of-Life Decision-Making Model for Older Adults with Acute Myeloid Leukemia.
For each PRO, we identified the first follow-up visit at which a patient’s score worsened by a clinically meaningful amount from baseline and compared the time to that event between treatment groups. QOL was assessed at baseline (day 0), day 30, day 60, day 90, and day 180. Clinically meaningful deterioration was defined using the following thresholds:
an increase of ≥10 points for Brief Fatigue Inventory (BFI)where higher scores= more fatigue,
an increase of ≥4.5 points for Memorial Symptoms Assessment Scale Global Distress Index (MSAS GDI) where higher scores = more distress,
a decrease of ≥7 points for Functional Assessment of Cancer Therapy -Leukemia (FACT-Leu) where lower scores = worse QOL.
The endpoint was a composite of QOL/PRO deterioration or death, whichever occurred first. The log-rank test was used to compare the median TTD of two treatment groups for BFI, MSAS GDI, or FACT-Leu.
Results: The study included 171 patients (82 intensive-treatment, 89 non-intensive-treatment) with a mean age of 70.6±6.5 years. Patients treated with non-intensive therapy were significantly older than those treated with intensive therapy (74.0 vs. 67.0 years, p<0.001). The cohort was predominantly male (65.5%), White non-Hispanic (91.1%), married (71.6%), retired (77.1%), and highly educated, with most patients having a bachelor's degree or higher. Baseline sociodemographic characteristics were otherwise similar between treatment groups.
Across all QOL/PRO instruments, intensive treatment was associated with significantly longer time to clinically meaningful worsening of QOL/PRO. Median TTD was approximately threefold longer in the intensive treatment group for BFI (6.0 vs. 2.0 months; log-rank p = 0.002) and MSAS GDI (8.7 vs. 3.0 months; log-rank p = 0.001), and nearly twofold longer for FACT-Leu (4.5 vs. 2.3 months; log-rank p = 0.02).
Patients receiving intensive treatment had a longer period before meaningful QOL and symptom deterioration. Previously reported survival from this data showed a longer survival for the intensive group.
Conclusion: In this exploratory analysis of older adults with AML, intensive treatment was associated with a significantly longer time to clinically meaningful deterioration in fatigue, symptom distress, and leukemia-specific QOL compared with non-intensive treatment. These findings suggest that intensive therapy may provide a longer period of preserved QOL and symptom control. The endpoint combined QOL deterioration and death, thus the observed differences may reflect both survival advantages and differences in baseline fitness between groups. Nevertheless, TTD analyses offer a clinically meaningful framework for incorporating PROs into shared decision-making and warrant further study in larger, more diverse populations.
DISCLOSURES
Sara M. Tinsley-Vance, PhD, APRN, AOCN: No relevant conflicts of interest to declare.